STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems

Cellular Signalling, Год журнала: 2025, Номер unknown, С. 111647 - 111647

Опубликована: Фев. 1, 2025

Язык: Английский

---

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Gut, Год журнала: 2024, Номер 74(1), С. 9 - 14

Опубликована: Июль 17, 2024

Despite significant advances in biologic and small molecule treatments the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains control intestinal inflammation. New approaches targeting several pathways simultaneously with favorable safety profile agents that trigger anti-inflammatory drive durable resolution inflammation are needed. This article discusses novel cellular immunotherapies immune cell depleting IBD, including CAR-T approaches, Tr1 T regulatory (Treg) cells antibodies such as rosnilimab. These have potential overcome current therapeutic limitations treatment IBD.

Язык: Английский

---

Synthetic Gene Circuits as a Promising Approach in Cancer Immunotherapy

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Год журнала: 2024, Номер unknown, С. 391 - 418

Опубликована: Авг. 28, 2024

Cancer immunotherapy has emerged as a revolutionary approach in the fight against cancer. Unlike traditional treatments like chemotherapy and radiation, harnesses power of body's own immune system to identify destroy cancer cells. promising therapy, but limitations specificity control hinder its full potential. Synthetic gene circuits offer address these challenges. This chapter emphasizes diverse applications synthetic immunotherapy. Additionally, authors discuss advantages AND gate for minimizing off-target effects, engineered bacteria targeted tumour manipulation, T-cell engineering enhanced anti-tumour activity. Ultimately, therapies are not mutually exclusive. While proven effectiveness accessibility, hold immense promise personalized, long-term solutions.

Язык: Английский

---

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

Nature Reviews Drug Discovery, Год журнала: 2024, Номер 24(1), С. 40 - 56

Опубликована: Ноя. 4, 2024

Язык: Английский

---

HEBE: A novel chimeric chronokine for ameliorating memory deficits in Alzheimer’s disease

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 183, С. 117815 - 117815

Опубликована: Янв. 15, 2025

Язык: Английский

---

CAR T-cell Therapy Landscape in Pediatric, Adolescent and Young Adult Oncology - A Comprehensive Analysis of Clinical Trials

Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер 209, С. 104648 - 104648

Опубликована: Фев. 1, 2025

Язык: Английский

---

CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges

Leukemia & lymphoma/Leukemia and lymphoma, Год журнала: 2025, Номер unknown, С. 1 - 13

Опубликована: Фев. 3, 2025

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive that isolated in the (CNS) or vitreoretinal space. High-dose methotrexate (HD-MTX)-based immunochemotherapy frontline for its treatment, with high early response rate. However, relapsed refractory (R/R) patients present numerous difficulties challenges clinical treatment. Chimeric antigen receptor (CAR)-T cells offer promising option treatment of hematologic malignancies, especially R/R B-cell multiple myeloma. Despite exclusion most PCNSL cases from pivotal CAR-T cell trials due to their specific tumor microenvironment (TME), available preclinical studies small cohorts suggest an overall acceptable safety profile remarkable anti-tumor effects. In this review, we will provide development process summarize research progress, limitations, future perspectives therapy PCNSL.

Язык: Английский

---

The potential applications of peptide-loading complex in cancer treatment

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 3, 2025

Immunotherapy for cancer has made significant strides in the last several years. The prognosis patients significantly improved as a result, particularly hematological diseases. However, it was discovered that translating these achievements to solid tumors proved challenging. peptide-loading complex (PLC), temporary multisubunit membrane assembly endoplasmic reticulum (ER), is crucial initiating hierarchical immune response. Chaperones calreticulin and tapasin make up PLC, unique class I glycoproteins, thiooxido-reductase ERp57, transporter associated with antigen processing. loading editing of major histocompatibility (MHC-I) molecules peptide translocation into ER are synchronized by PLC. One escape strategies revealed so far changes expression MHC molecules. This because antigens presenting T-lymphocytes controlling NK cell activity. Furthermore, decreased MHC-I been linked malignancies resistant T-cell-based immunotherapies (adoptive transfer antitumor CD8 T-cells or checkpoint inhibition). PLC essential T-cell priming, differentiation, tumor growth control can bind wide range allomorphs. In this review, we have looked PLC’s function effects all forms improve therapy techniques.

Язык: Английский

---

The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(3), С. 176 - 176

Опубликована: Март 7, 2025

Chemotherapeutic agents play a crucial role in cancer treatment. However, their use is often associated with significant adverse effects, particularly cardiotoxicity. Drugs such as anthracyclines (e.g., doxorubicin) and platinum-based cisplatin) cause mitochondrial damage, which one of the main mechanisms underlying These drugs induce oxidative stress, leading to an increase reactive oxygen species (ROS), turn damage mitochondria cardiomyocytes, resulting impaired cardiac function heart failure. Mitochondria-targeted antioxidants (MTAs) have emerged promising cardioprotective strategy, offering potential solution. efficiently scavenge ROS within mitochondria, protecting cardiomyocytes from damage. Recent studies shown that MTAs, elamipretide, SkQ1, CoQ10, melatonin, significantly mitigate chemotherapy-induced not only reduce but also help maintain structure function, stabilize membrane potential, prevent excessive opening permeability transition pore, thus preventing apoptosis dysfunction. In this review, we integrate recent findings elucidate cardiotoxicity highlight substantial therapeutic MTAs reducing are expected offer safer more effective treatment options for patients clinical practice.

Язык: Английский

---

Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy

European Journal Of Haematology, Год журнала: 2025, Номер unknown

Опубликована: Март 11, 2025

ABSTRACT Although small molecule inhibitors that target the aberrant signaling pathways and molecular defects of chronic lymphocytic leukemia (CLL) result in improved survival benefits vs. traditional chemoimmunotherapy or chemotherapy, treatment resistance may later, reflecting intrinsic tumor heterogeneity, persistence leukemic clone, presence microenvironment, which supports disease clone. Patients with CLL have immune‐related abnormalities T lymphocyte subset composition, immune synapse formation, other dysregulations. Cellular interactions between clone its microenvironment provide therapeutic opportunities to these pathogenesis pathways, potentially improving patient's functions clinical outcomes targeted therapies. At present, despite lack response checkpoint CLL, they showed promising efficacy patients Richter transformation. Together CD19‐targeted chimeric antigen receptor–modified cell (CAR‐T) therapy, novel bispecific antibodies immunotherapies are being investigated improve for relapsed refractory (R/R) as exemplified by epcoritamab, a antibody recently demonstrated initial R/R high‐risk subgroups, including those TP53 aberrations unmutated genes encode immunoglobulin variable heavy chain region ( IGHV ). Furthermore, address escape cancer cells issues impact durability single‐targeted cell‐redirected therapies, strategies such trispecific combination therapies increase specificity activation. In summary, there is emerging evidence counteract immunosuppressive responses, decrease risk infection, overcome resistance.

Язык: Английский

---